Adagene Inc. develops antibody-based cancer immunotherapies as a Nasdaq-listed foreign issuer whose securities trade as ADSs under ADAG. The company uses computational biology and artificial intelligence through its proprietary Dynamic Precision Library platform, including NEObody, SAFEbody and POWERbody technologies, to design masked and engineered antibody programs.
Recurring company updates center on muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody, clinical data in microsatellite stable colorectal cancer and hepatocellular carcinoma, combination studies with checkpoint and bispecific therapies, and FDA Fast Track designation in MSS metastatic colorectal cancer. Other developments include scientific meeting presentations, SAFEbody collaborations and licensing, advisory board changes, financial results and ADS capital offerings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Adagene Inc. (Nasdaq: ADAG) has reported promising interim results from its ongoing phase 1b/2 trials for ADG126, a masked anti-CTLA-4 SAFEbody. The trials, which presented findings at the AACR Annual Meeting, highlight a combination therapy with anti-PD-1 treatments showing tumor shrinkage and stable disease in previously untreated patients. Specifically, 22.6% of patients experienced Grade 3 treatment-related adverse events (TRAEs), indicating a best-in-class safety profile. Notably, clinical responses were observed with three partial responses and significant tumor shrinkage in patients with metastatic colorectal cancer. Additionally, ongoing dose expansion studies aim to further evaluate disease control rates and overall survival. Partnerships with Roche are also set to explore ADG126 in combination with other therapies for advanced HCC.
Adagene Inc. (Nasdaq: ADAG) reported its financial results for 2022, highlighting a cash balance of US$143.8 million to support operations through 2025. The company presented favorable clinical data for its anti-CTLA-4 programs, including ADG116 and ADG126, demonstrating best-in-class safety and efficacy profiles. Collaborations with Roche and Sanofi offer a potential multi-billion dollar non-dilutive funding opportunity. However, Adagene experienced a net loss of US$80.0 million, reflecting increased R&D expenses to advance its pipeline. Positive trial results and strategic collaborations aim to enhance shareholder value.
Adagene Inc. (Nasdaq: ADAG) announced significant developments in its clinical trials during the AACR Annual Meeting 2023. Key highlights include the presentation of ADG126 phase 1b/2 trial results, showcasing its effectiveness in combination with anti-PD-1 therapies. Findings indicate compelling safety and confirmed clinical responses, with particular attention to late-onset toxicity when combined with pembrolizumab. Additionally, details on ADG153, a new masked anti-CD47 IgG1 SAFEbody, reveal strong anti-tumor activity in preclinical models. Presentations are scheduled from April 14-19, 2023, in Orlando, Florida.